Copanlisib

Intravenous administration separates copanlisib from the oral inhibitors that dominate its class. The agent is a pan-PI3K inhibitor with predominant activity against the alpha and delta isoforms of phosphoinositide 3-kinase, a pathway that supports tumour cell growth and survival. Inhibiting the delta isoform addresses B-cell receptor signalling in lymphoid malignancy, while alpha-isoform activity extends the pharmacology beyond the lymphocyte lineage. Approval covers relapsed follicular lymphoma, placing it among the treatment options after earlier regimens have failed. The molecule has the formula C23H28N8O4 and a molecular weight of approximately 480.5 g/mol. It is an approved small-molecule agent that has completed the final phase of clinical development.

SMILES

COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21

InChI

InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)